Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.07 | -$0.05 | -$0.06 |
| Q2 2026 | 1 | -$0.07 | -$0.05 | -$0.06 |
| Q3 2026 | 1 | -$0.07 | -$0.05 | -$0.06 |
| Q4 2026 | 1 | -$0.04 | -$0.03 | -$0.03 |
Sangamo Therapeutics Inc last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.11 earnings per share for the quarter, missing analysts' consensus estimates of $-0.03 by $0.08. The company had revenue of 581.00 K for the quarter and had revenue of 57.80 M for the year. Sangamo Therapeutics Inc has generated $0 earnings per share over the last year ($-0.49 diluted earnings per share) and currently has a price-to-earnings ratio of -1.08. Sangamo Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.03 | -$0.11 | -0.08 | $34.40 M | $581.00 K |
| 08/07/2025 | Q2 2025 | -$0.07 | -$0.08 | -0.01 | $31.68 M | $18.31 M |
| 05/12/2025 | Q1 2025 | -$0.11 | -$0.14 | -0.03 | N/A | $6.44 M |
| 03/17/2025 | Q4 2024 | -$0.09 | -$0.11 | -0.02 | N/A | $7.55 M |
| 11/12/2024 | Q3 2024 | $0.01 | $0.05 | 0.03 | $20.92 M | $49.41 M |
| 08/06/2024 | Q2 2024 | -$0.16 | -$0.18 | -0.02 | $6.88 M | $356.00 K |
| 05/09/2024 | Q1 2024 | -$0.22 | -$0.27 | -0.05 | N/A | $481.00 K |
| 03/13/2024 | Q4 2023 | -$0.25 | -$0.34 | -0.09 | N/A | $2.04 M |
| 11/01/2023 | Q3 2023 | -$0.33 | -$0.59 | -0.26 | N/A | $9.40 M |
| 08/08/2023 | Q2 2023 | -$0.35 | -$0.66 | -0.31 | N/A | $6.84 M |
| 05/08/2023 | Q1 2023 | -$0.33 | $0.13 | 0.46 | N/A | $157.96 M |
| 02/22/2023 | Q4 2022 | N/A | -$0.32 | N/A | N/A | $27.23 M |
| 11/03/2022 | Q3 2022 | -$0.35 | -$0.34 | 0.01 | N/A | $26.46 M |
| 08/04/2022 | Q2 2022 | -$0.35 | -$0.29 | 0.06 | N/A | $29.38 M |
| 05/05/2022 | Q1 2022 | -$0.32 | -$0.30 | 0.02 | N/A | $28.23 M |
| 02/24/2022 | Q4 2021 | -$0.34 | -$0.26 | 0.08 | N/A | $27.99 M |
| 11/04/2021 | Q3 2021 | -$0.34 | -$0.33 | 0.01 | N/A | $28.56 M |
| 08/05/2021 | Q2 2021 | -$0.30 | -$0.33 | -0.03 | N/A | $27.87 M |
| 05/04/2021 | Q1 2021 | -$0.29 | -$0.32 | -0.03 | N/A | $26.28 M |
| 02/24/2021 | Q4 2020 | -$0.18 | -$0.29 | -0.11 | N/A | $25.80 M |
The conference call for Sangamo Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Sangamo Therapeutics Inc's latest earnings report can be read online.
Sangamo Therapeutics Inc (:SGMO) has a recorded annual revenue of $57.80 M.
Sangamo Therapeutics Inc (:SGMO) has a recorded net income of $-97,941,000.Sangamo Therapeutics Inc has generated $-0.49 earnings per share over the last four quarters.
Sangamo Therapeutics Inc (:SGMO) has a price-to-earnings ratio of -1.08 and price/earnings-to-growth ratio is 0.02.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED